ReShape Gross Profit from 2010 to 2025

RSLS Stock

USD 0.63 0.03 4.55%

ReShape Lifesciences Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit will likely drop to about 3.2 M in 2025. Gross Profit is the profit ReShape Lifesciences makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2005-12-31

Previous Quarter

1.1 M

Current Value

1.4 M

Quarterly Volatility

890 K

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 22.2 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many indicators such as Price To Sales Ratio of 0.19, Dividend Yield of 0.0 or PTB Ratio of 0.24. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.

Check out the analysis of ReShape Lifesciences Correlation against competitors.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

Latest ReShape Lifesciences' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of ReShape Lifesciences over the last few years. Gross profit is a required income statement account that reflects total revenue of ReShape Lifesciences minus its cost of goods sold. It is profit before ReShape Lifesciences operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. ReShape Lifesciences' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 6.8 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

ReShape Gross Profit Regression Statistics

	Arithmetic Mean	2,957,122
	Geometric Mean	0.00
	Coefficient Of Variation	118.44
	Mean Deviation	3,142,345
	Median	442,411
	Standard Deviation	3,502,472
	Sample Variance	12.3T
	Range	9.3M
	R-Value	0.73
	Mean Square Error	6.1T
	R-Squared	0.54
	Significance	0
	Slope	540,209
	Total Sum of Squares	184T

ReShape Gross Profit History

	2025	3.2 M
	2024	6.4 M
	2023	5.5 M
	2022	6.8 M
	2021	8.3 M
	2020	6.3 M
	2019	9.3 M

Other Fundumenentals of ReShape Lifesciences

Gross Profit Margin

ReShape Lifesciences Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Net Debt	Accounts Payable	Long Term Debt	Net Receivables	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Short Term Investments	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	-0.1	0.58	-0.31	0.32	-0.21	0.22	0.29	0.25	0.14	0.03	0.38	0.28	-0.07	-0.04	0.23	0.28	0.13	0.11	0.05
Total Stockholder Equity	0.97		-0.1	0.38	-0.32	0.25	-0.22	0.17	0.28	0.21	0.11	0.11	0.47	0.27	0.04	-0.01	0.22	0.28	0.15	0.25	0.07
Retained Earnings	-0.1	-0.1		-0.04	-0.23	-0.7	-0.54	-0.76	0.24	0.31	0.52	-0.32	0.32	-0.59	0.41	-0.75	-0.92	-0.43	0.88	0.03	0.85
Total Liab	0.58	0.38	-0.04		-0.09	0.38	-0.09	0.29	0.15	0.29	0.19	-0.26	-0.16	0.2	-0.46	-0.1	0.12	0.11	-0.02	-0.45	-0.07
Net Debt	-0.31	-0.32	-0.23	-0.09		0.21	0.09	0.2	-0.95	0.04	-0.5	-0.55	0.15	0.14	-0.71	0.14	0.33	0.12	-0.45	-0.68	-0.22
Accounts Payable	0.32	0.25	-0.7	0.38	0.21		0.39	0.96	-0.19	-0.31	-0.57	0.17	-0.19	0.5	-0.37	0.47	0.8	0.53	-0.64	-0.1	-0.8
Long Term Debt	-0.21	-0.22	-0.54	-0.09	0.09	0.39		0.47	0.06	-0.35	-0.51	0.62	-0.23	0.19	0.08	0.83	0.51	0.34	-0.71	0.08	-0.69
Net Receivables	0.22	0.17	-0.76	0.29	0.2	0.96	0.47		-0.17	-0.39	-0.56	0.22	-0.21	0.44	-0.33	0.49	0.84	0.48	-0.73	-0.11	-0.89
Total Current Assets	0.29	0.28	0.24	0.15	-0.95	-0.19	0.06	-0.17		0.04	0.47	0.52	-0.22	-0.17	0.7	-0.07	-0.35	-0.11	0.36	0.59	0.18
Short Term Debt	0.25	0.21	0.31	0.29	0.04	-0.31	-0.35	-0.39	0.04		0.37	-0.41	-0.11	-0.16	-0.14	-0.41	-0.27	0.0	0.29	-0.19	0.59
Common Stock	0.14	0.11	0.52	0.19	-0.5	-0.57	-0.51	-0.56	0.47	0.37		-0.1	-0.15	-0.56	0.2	-0.57	-0.59	-0.17	0.61	0.09	0.59
Property Plant Equipment	0.03	0.11	-0.32	-0.26	-0.55	0.17	0.62	0.22	0.52	-0.41	-0.1		-0.1	0.03	0.61	0.52	0.27	0.19	-0.18	0.75	-0.37
Short Term Investments	0.38	0.47	0.32	-0.16	0.15	-0.19	-0.23	-0.21	-0.22	-0.11	-0.15	-0.1		-0.06	0.1	-0.19	-0.12	-0.13	0.32	0.05	0.29
Current Deferred Revenue	0.28	0.27	-0.59	0.2	0.14	0.5	0.19	0.44	-0.17	-0.16	-0.56	0.03	-0.06		-0.26	0.56	0.53	0.22	-0.45	-0.06	-0.42
Net Tangible Assets	-0.07	0.04	0.41	-0.46	-0.71	-0.37	0.08	-0.33	0.7	-0.14	0.2	0.61	0.1	-0.26		-0.1	-0.45	-0.15	0.47	0.8	0.29
Long Term Debt Total	-0.04	-0.01	-0.75	-0.1	0.14	0.47	0.83	0.49	-0.07	-0.41	-0.57	0.52	-0.19	0.56	-0.1		0.68	0.48	-0.78	0.1	-0.72
Capital Surpluse	0.23	0.22	-0.92	0.12	0.33	0.8	0.51	0.84	-0.35	-0.27	-0.59	0.27	-0.12	0.53	-0.45	0.68		0.57	-0.84	-0.08	-0.83
Short Long Term Debt	0.28	0.28	-0.43	0.11	0.12	0.53	0.34	0.48	-0.11	0.0	-0.17	0.19	-0.13	0.22	-0.15	0.48	0.57		-0.44	-0.06	-0.41
Net Invested Capital	0.13	0.15	0.88	-0.02	-0.45	-0.64	-0.71	-0.73	0.36	0.29	0.61	-0.18	0.32	-0.45	0.47	-0.78	-0.84	-0.44		0.3	0.88
Net Working Capital	0.11	0.25	0.03	-0.45	-0.68	-0.1	0.08	-0.11	0.59	-0.19	0.09	0.75	0.05	-0.06	0.8	0.1	-0.08	-0.06	0.3		0.1
Capital Stock	0.05	0.07	0.85	-0.07	-0.22	-0.8	-0.69	-0.89	0.18	0.59	0.59	-0.37	0.29	-0.42	0.29	-0.72	-0.83	-0.41	0.88	0.1

Click cells to compare fundamentals

About ReShape Lifesciences Financial Statements

ReShape Lifesciences shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may analyze each financial statement separately, they are all interrelated. The changes in ReShape Lifesciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on ReShape Lifesciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	6.4 M	3.2 M
Gross Profit Margin	0.58	0.42

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC